UGT1A9 and colorectal carcinoma: Dapagliflozin counteracted tumor growth, abrogating the hyperinsulinemia cancer-promoting effect in both in vivo and in vitro CRC models [185], and reducing cell adhesion, inducing loss of interaction with collagen I and IV associated with reduced Discoidin domain receptor family member 1 (DDR1) function in HCT116 cells not expressing the SGLT2 catabolizer UDP Glucuronosyltransferase Family 1 Member A9 (UGT1A9) [185].